白杨素偶联一氧化氮供体衍生物的合成及α-葡萄糖苷酶抑制和促血管生成活性研究
|
摘要
NO作为一种重要的信使物质和生物活性物质,参与调节机体的一系列生理活动以及新生血管生成等病理生理过程,调节血管内皮生长,触发血管活性物质,促进血管生长与再生。而NO供体则是在体内经酶或非酶作用能释放NO。近来人们为了增加药物的活性,已经开始趋向于把NO供体结构引入到已知药物分子中去。
白杨素,化学名为5,7-二羟基黄酮,是以C6-C3-C6结构为基本母核的天然有机化合物。具有一些重要的特性,如:高度的化学反应性,易进行结构修饰;很多重要的药理作用,具有抗氧化、抗焦虑、抗菌、抗癌﹑抗高血压﹑抗病毒等作用。近年来,为获得疗效更好的新型药物,开始了对白杨素进行结构修饰和化学合成。但对白杨素衍生物抗糖尿病及其并发症药物的设计开发处于起步阶段。
因此,在本文中我们将设计合成几类白杨素偶联不同一氧化氮供体衍生物新型化合物,期望能同时具有α-葡萄糖苷酶抑制活性和促血管生成作用,为开发糖尿病及其血管并发症药物提供候选化合物。合成路线是以白杨素为母核,将不同类型的NO供体通过不同结构的中间链与白杨素7位活性羟基偶联,或同时在把5位羟基乙酰化。最后得到3种不同类型5个系列共16个未见文献报道的新化合物,其中包括有机硝酸酯类2个系列共9个,呋咱氮氧化物类2个系列共6个、N-羟基胍类1个系列共1个,所有目标化合物均由核磁共振氢谱、质谱等表征确认其结构。对所合成的硝酸酯偶联白杨素衍生物9个和呋咱氮氧化物偶联白杨素衍生物6个共15个,分别进行了体外α-葡萄糖苷酶抑制活性实验, MTT细胞毒性和CAM血管生成实验。发现所有15个化合物都具有α-葡萄糖酶抑制活性,其中6个化合物(7b、17、18、15b、15a、16b)的IC50值都在20μmol/L以下,酶抑制活性大大超过阳性对照药阿卡波糖;在MTT体外实验中,10μmol/L浓度下,所有目标化合物均未表现出细胞毒性,其中7a、7b、7c、5a、5b、5c、17目标化合物对HUVECs-12具有一定的促细胞增殖作用;在CAM体内实验中,目标化合物7a、7b、7c、5a、5b、5c、17、15b、15a、16b、16a促血管生成活性作用明显。
根据药理实验,所合成的目标化合物中有5个(7b、17、15b、15a、16b)既有较好的α-葡萄糖苷酶抑制活性,又有较强促血管生成能力,这5个目标化合物在开发糖尿病及其血管并发症药物方面具有很好的潜力,值得深入研究。
As an important messenger and biotic activator, mononitrogen monoxide (NO) was believed involved the physiology activity, promotion angiogenesis, accommodation blood vessel- endothelium growth. NO donor in the body by the enzyme or non-enzymatic can be released NO. Recently, people in order to increase the activity of drugs, have begun to tend to the NO donor into the structure of drug molecules.
With C6-C3-C6 as the fundamental structure, chrysin (5,7-dihydroxyflavone) is a naturally wide distributed flavonoid, which has been reported to have many different biological activities such as anti-viral, anti-cancer, anti-bactericidal, anti-flammatory, anti-allergic, DNA cleavage, vasodilator, anti-mutagenic, anti-anxiolytic and anti-oxidant effects. To get better therapeutic effect, much effort has been devoted to the modification and chemical synthesis of chrysin in recent years. However, the research on the role of chyrin and its derivatives in anti-diabetes and anti-diabetic vascular complications is still in its infant stage.
Different chrysin derivatives were successfully coupled to NO donors and we hope this kind of compounds could act asα-Glucosidase Inhibition reagents and promotion angiogenesis reagents as well as anti-diabetes and anti-diabetic vascular complications. Using chrysin as the starting material, different NO donors were coupled to the active hydroxy group at the 7-position of chrysin and acetylation of hydroxy group at the 5-position could be occurred at the same time. Thus 16 new compounds (including 9 nitro ester compounds, 6 furazan derivatives and 1 N-hydroxy carbamidine compound) were prepared by similar method and all of them were characterized by means of 1H NMR and MS (EI).
In vivoα-glucosidase inhibition, MTT cell proliferation and CAM angiogenesis experiments were performed to evaluate these compounds’activity. It was found that all of the 9 nitro ester compounds and 6 furazan compounds showedα-glucosidase inhibition activity, among them, 6 compounds’(7b, 17, 18, 15b, 15a, 16b) IC50 value are less than 20μmol/L, which is much better than the reference compound acarbose. All target compounds did not show any cytotoxicity in the MTT in vivo experiments under 10μmol/L concentration, however, 7a, 7b, 7c, 5a, 5b, 5c and 17 exhibited cell proliferation activity on HUVECs-12. In the meantime, among those 15 compounds investigated by CAM assay, 7a, 7b, 7c, 5a, 5b, 5c, 17, 15b, 15a, 16b and 16a showed strong angiogenic activities.
These results indicated that these compounds we prepared have excellent angiogenic activity in vivo andα-glucosidase inhibition activity, among them compounds 7b, 17, 15b, 15a and 16b are the best and worth for further investigation for anti-diabetes and anti-diabetic vascular complications applications.
白杨素,化学名为5,7-二羟基黄酮,是以C6-C3-C6结构为基本母核的天然有机化合物。具有一些重要的特性,如:高度的化学反应性,易进行结构修饰;很多重要的药理作用,具有抗氧化、抗焦虑、抗菌、抗癌﹑抗高血压﹑抗病毒等作用。近年来,为获得疗效更好的新型药物,开始了对白杨素进行结构修饰和化学合成。但对白杨素衍生物抗糖尿病及其并发症药物的设计开发处于起步阶段。
因此,在本文中我们将设计合成几类白杨素偶联不同一氧化氮供体衍生物新型化合物,期望能同时具有α-葡萄糖苷酶抑制活性和促血管生成作用,为开发糖尿病及其血管并发症药物提供候选化合物。合成路线是以白杨素为母核,将不同类型的NO供体通过不同结构的中间链与白杨素7位活性羟基偶联,或同时在把5位羟基乙酰化。最后得到3种不同类型5个系列共16个未见文献报道的新化合物,其中包括有机硝酸酯类2个系列共9个,呋咱氮氧化物类2个系列共6个、N-羟基胍类1个系列共1个,所有目标化合物均由核磁共振氢谱、质谱等表征确认其结构。对所合成的硝酸酯偶联白杨素衍生物9个和呋咱氮氧化物偶联白杨素衍生物6个共15个,分别进行了体外α-葡萄糖苷酶抑制活性实验, MTT细胞毒性和CAM血管生成实验。发现所有15个化合物都具有α-葡萄糖酶抑制活性,其中6个化合物(7b、17、18、15b、15a、16b)的IC50值都在20μmol/L以下,酶抑制活性大大超过阳性对照药阿卡波糖;在MTT体外实验中,10μmol/L浓度下,所有目标化合物均未表现出细胞毒性,其中7a、7b、7c、5a、5b、5c、17目标化合物对HUVECs-12具有一定的促细胞增殖作用;在CAM体内实验中,目标化合物7a、7b、7c、5a、5b、5c、17、15b、15a、16b、16a促血管生成活性作用明显。
根据药理实验,所合成的目标化合物中有5个(7b、17、15b、15a、16b)既有较好的α-葡萄糖苷酶抑制活性,又有较强促血管生成能力,这5个目标化合物在开发糖尿病及其血管并发症药物方面具有很好的潜力,值得深入研究。
As an important messenger and biotic activator, mononitrogen monoxide (NO) was believed involved the physiology activity, promotion angiogenesis, accommodation blood vessel- endothelium growth. NO donor in the body by the enzyme or non-enzymatic can be released NO. Recently, people in order to increase the activity of drugs, have begun to tend to the NO donor into the structure of drug molecules.
With C6-C3-C6 as the fundamental structure, chrysin (5,7-dihydroxyflavone) is a naturally wide distributed flavonoid, which has been reported to have many different biological activities such as anti-viral, anti-cancer, anti-bactericidal, anti-flammatory, anti-allergic, DNA cleavage, vasodilator, anti-mutagenic, anti-anxiolytic and anti-oxidant effects. To get better therapeutic effect, much effort has been devoted to the modification and chemical synthesis of chrysin in recent years. However, the research on the role of chyrin and its derivatives in anti-diabetes and anti-diabetic vascular complications is still in its infant stage.
Different chrysin derivatives were successfully coupled to NO donors and we hope this kind of compounds could act asα-Glucosidase Inhibition reagents and promotion angiogenesis reagents as well as anti-diabetes and anti-diabetic vascular complications. Using chrysin as the starting material, different NO donors were coupled to the active hydroxy group at the 7-position of chrysin and acetylation of hydroxy group at the 5-position could be occurred at the same time. Thus 16 new compounds (including 9 nitro ester compounds, 6 furazan derivatives and 1 N-hydroxy carbamidine compound) were prepared by similar method and all of them were characterized by means of 1H NMR and MS (EI).
In vivoα-glucosidase inhibition, MTT cell proliferation and CAM angiogenesis experiments were performed to evaluate these compounds’activity. It was found that all of the 9 nitro ester compounds and 6 furazan compounds showedα-glucosidase inhibition activity, among them, 6 compounds’(7b, 17, 18, 15b, 15a, 16b) IC50 value are less than 20μmol/L, which is much better than the reference compound acarbose. All target compounds did not show any cytotoxicity in the MTT in vivo experiments under 10μmol/L concentration, however, 7a, 7b, 7c, 5a, 5b, 5c and 17 exhibited cell proliferation activity on HUVECs-12. In the meantime, among those 15 compounds investigated by CAM assay, 7a, 7b, 7c, 5a, 5b, 5c, 17, 15b, 15a, 16b and 16a showed strong angiogenic activities.
These results indicated that these compounds we prepared have excellent angiogenic activity in vivo andα-glucosidase inhibition activity, among them compounds 7b, 17, 15b, 15a and 16b are the best and worth for further investigation for anti-diabetes and anti-diabetic vascular complications applications.
引文
[1] Palmer R M J,Ferrige A G,Moncada S.Nitric oxide release accounts for the biological activity of endothelium -derived relaxing factor[J].Nature,1987,327(11):524-526.
[2] Robert W,Mcpherson,Jeffrey R,et a1.Effect of nitric oxide synthase inhibition on the cerebral vascular response to hypercapnia in primates.Stroke,1995,26:682-687.
[3] Faraci F M,Brian J E.Nitric oxide and the cerebral circulation[J].Stroke,1994,25:692-703.
[4] Bredt D S,Snyder S H.Nitric:A physiologic messenger molecuiar[J].Annual Review of Biochemistry,1994,63:175-195.
[5]张忠.一氧化氮与脑循环[J].国外医学-内科学分册,1996,23(8):337-339.
[6] Ziche M,Morbidelli L,Masini E,et al.Nitric oxide mediates angiogenesis in vivo and endothelial cell growth and migration in vitro promoted by substance[J].J Clin Invest l994,94:2036-2044.
[7] Wilkinson-Berka J L.Vasoactive factors and diabetic retinopathy:vascular endothelia growth factor,cycoloxygenase-2 and nitric oxide[J].Curr Pha Des,2004,10(27):333l-3348.
[8]伍欣星,聂广.医学分子生物学原理与方法[M].北京:科学出版杜,2000,267-269.
[9] Myers P R,Minor R L,G uerraR,et al.Vasorelaxant properties of the endothelium- derived relaxing factor more closely resemble S–nitrosocysteine than nitric oxide[J].Nature,1990,345:161-163.
[10] Rosenblum W I.Endothelium-derived relaxing factor in rain blood vessels is not nitric oxide[J].stroke,1992,23:1527-1532.
[11] Moncada S,Higgs A,Fuchgott F R.International union of pharmacology nomenclature in nitric oxide research[J].Pharmacol Rev,1997,49:137-142.
[12] Faraci F M,Heistad D D.Regulation of the cerebral circulation:role of endothelium and potassium channels[J].Physiol Rev,1998,78(1):53-97.
[13] Megson I L.Nitric oxide donor drugs[J].Drugs of the Future,2000,25(7):70l-705.
[14] Searena R,Bottoni P,Martorana G E,et al.Nitric oxide donor drugs:an update on pathophysiology and therapeutic potential[J].Expert Opinion on Investigational Drugs,2005,14(7):835-846.
[15] Roberts J D,Polaner D M,Lang P,et al.Inhaled nitrico xide in persistent pulmonary hypertension of the newborn[J].Lancet,1992,340:818-819.
[16] Kinsella J P,Neish S R,Shaffer E,et al.Low-dose inhala-tional nitricoxide in persistent pulmonary hypertension of the newborn[J].Lancet,1992,340:819-820.
[17] Feelisch M.The biochemical pathways of nitric oxide formation from nitrovasodilators:appropriate choice of exogenous NO donors and a spects of preparation and handling of aqueous NO solutions[J].Journal of Cardiovascular Pharmacology,1991,17(Suppi.3):S 25-S33.
[18] Stamler J S, Singel D J, Loscalzo J.Biochemistry of nitric oxide and its redox- activated forms[J].Science,1992,258:1898-1902.
[19] Hou Y C,Janczuk A,Wang P G.Current trends in the development of nitric oxide donors[J].Current pharmaceutical design,1999,5(6):417-441.
[20] Wang P C,Xian M,Tang X,et al.Nitric oxide donors and biological applications[J]. Chem. Rev. ,2002,102(4):1091-1134.
[21] Cirino G.Nitric oxide releasing drugs:from bench to bedside[J].Digestive and Liver Disease,2003,35(Suppl 2):2-8.
[22]李松,陈畅,史艳秋,等.一氧化氮供体最新研究进展及应用前景[J].中国生化药物杂志,2006,27(6):374-379.
[23] Wallce J L,McknJight W,Wilson TL,et al.Reduction of shock-induced gastric damage by a nitric oxide-releasing aspirin derivative:role of neutrophils[J].American Journal of Physiology,1997,273(6):l246-l252.
[24] Li Y Q, Ji H, Zhang Y H,et al.A novel nitric oxide-releasing derivative of elm-isartan,inhibits hypertension and improves glucose metabolism in rats[J].European Journal of Pharmacology,2007,1-3(577):100-108.
[25] Wang H K,Xia Y,Yang ZY,et al.Recent advances in the discovery and development of flavonoids and their analogues as antitumor and anti-HIV agents[J]. Adv. Exp. Med. Biol.,1998,439:191-225.
[26]陈莉,张奕华.前药原理在非甾体抗炎药中的应用[J].中国药师,2003,6(1):50-52.
[27] Bandarage U K,Chen L,Fang X,et a1.Nitrosothiol esters of diclofenac:synthesis and pharmacological characterization as gastrointestinal-sparing prodrugs[J]. J. Med. Chem.,2000,43(21):4005-4016.
[28] De Tejada I S,Garvey D S,Sehroeder J D,et a1.Design and evaluation of nitrosylated alpha-adrenergic receptor antagonists a potential agents for the treatment of impotence[J].J.Pharmaeol.Exp.Ther.,1999,290(I):121-128.
[29] Whittle B R J.Temporal relationship between cycloxygenase inhibition,as measured by prostaglandin biosynthesis,and the gastrointestinal damage induced by indomethacin in the rat[J].Gastroenterology,1981,80:94-98.
[30] Lechi C,Andrioli G,Guino S,et al.The antiplatelet effects of a new nitroderivative of acetylsalicylic acid- an in vitro study of inhibition on the early phase of platelet activation and on TXA2 proltuction[J].Thromb Haemost,1996,76(5):791-798.
[31] Wallace J L,Muscara M N,McKnight W,et a1.In vivo antithrombotie effects of a nitric oxide-releasing aspirin derivative,NCX-4016[J],Thromb.Res.,1999,93(1):43-50.
[32] Wallace J L,Vergnolle N,Muscara M N, et a1.Enhanced anti-inflammatory effects of a nitri oxide-releasing derivative of mesalamine in rats[J], Gastroenterology,1999,117(3):557-566.
[33] Paul-Clark M,Del Soldato P,Fiorucci S,et al.21-NO-prednisolone is a novel nitric oxide-releasing derivative of prednisolone with enhanced anti- inflammatory properties[J].Br.J.Pharmacol.,2000,131(7):1345-1354.
[34] Ricardo de L B,Carlos Roque D C,Marcelo N M, Nitric oxide:properties and therapeutic use[J].Química Nova,2005,28(6):1046-1054.
[35] Endres S,HackerA,Noack E,et a1.NO-Donors,part 3:nitrooxyacylated thiosalicylates and salicylates synthesis and biological aetivities[J].Eur.J.Med.Chem.,1999,34(11):895-901.
[36] Ricardo de L B,Carlos Roque D C,Marcelo N M.Nitric oxide:properties and therapeutic use[J].Química Nova,2005,28(6):1046-1054.
[37] Lehmann J,Kahlich R,Meyer zum Gottesberge C,el al. Organic nitrates.II.Synthesis and biological activities of 4-nitrooxymethylphenyl 1,4-dihydropyridines[J]. Arch.Pharm.,1997,330(8):247-252.
[38] Haj-Yetlla A,Nassar T,Lntan C,et a1.Development of 3-nitratomethyl-proxyl (NMP):a novel,bifunctional superoxide dismutase-mimic-nitricoxide-donor [J].Drug.Dev.Res.,2000,50(3-4):528-536.
[39] Fruttero R,Boschi D,Di Stilo A,et a1.Tile furoxan system as a useful tool for balancing“hybrids”with mixed alpha 1-antagonist and NO-like vasodilator activitiesl [J].J.Med.Chem.,1995,38(25):4944-4949.
[40] Di Stilo A,Viscntin S,Cena C,et a1.NO donor and biological properties of different benzofuroxans endowed with both nitric oxide-1ike and calcium channel antagonist vasodilator activities[J].J.Med.Chem.,1998,41(27):5393-5401.
[41] Visentin S,Amiel P,Frultero R,et al.Synthesis and voltage-clamp studies of methyl 1,4-dihydro-2 , 6-dimethyl-5-nitro-4-(benzofurazany1) pyridine -3-carhoxylate racemates and enanliomers and of their benzofuroxanyl analogues[J]. J. Med. Chem.,1999,42(8):1422-1427.
[42] Mu L,Feng S S,Go M I.A Study of synthesis and cardiovascular activity of some furoxan derivatives as potential NO-donors[J].Chem.Pharm.Bull.,2000,48(6):808-816.
[43] Saavedra J E,Shami P J,Wang I Y,et a1, Esterase-sensitive nitric oxide donors of the diazeniumdiolate family in vitro antileukemic activity[J],J Med Chem,2000,43(2):261-269.
[44] Hou Yongchun,Xie Wenhua,Wang Peng George,et a1.O-Alkylation of cupferron:aiming at the design and synthesis of controlled nitric oxide releasing agents[J]. J.Org.Chem.,2000,65(14):4333-4337.
[45] Tang Xiaoping,Xian Ming,Wang Peng George,et a1.Synitlesis of peptide- diazeniumdiolate conjugate:towards enzyme activated antitumor agents[J]. Tetrahedron Lett.,2001,42:2625-2629.
[46] Wu Xuejun,Tang Xiaoping,Wang Peng George,et a1.Glyeosylated diazeniumdiolates:anovel class of enzyme-activated nitric oxide donors [J]. Tetrahedron Lett.,2001,42:3779-3782.
[47] Risau W.Mechanisms of angiogenesis[J].Nature,1997,386:671-674.
[48] Hershey J C,BaskinE P,Glass J D,et a1.Revascularization in the rabbit hindlimb:dissociation between capillary sprouting and arteriogenesis[J].Cardiovasc Res,2001,49:618-625.
[49] Risau W.Mechanisms of angiogenesis[J].Nature,1997,386:671-674.
[50] Folkman J.Angiogenesiain cancer,vascular,rheumatoid and other disease[J]. Nat. Med. ,1995,l(1):27-31.
[51]卞修武,史景泉.血管内皮生长因子及其受体在肿瘤血管生成中的作用与抗血管生成研究进展[J].中华病理学杂志,1997,26(4):248-250.
[52] Bian X W,Du L L,Shi J Q.Correlation of bFGF,FGFR-1 and VEGF expression with vascularity and malignancy of human astrocytomas[J].Analyt Quant Cytol Histo1,2000,22(3):267-274.
[53]孙慧勤,邹仲敏,卞修武,等.正常血管和肿瘤血管生成的调节机制研究进展[J].中华病理学杂志,2000,29(3):224-226.
[54] Fidler I J.Angiogenesis and cancer metastasis[J].Cancer J.,2000,(suppl2): 134-141.
[55] Simons M,Bonow R O,Chronos N A,et al.Clinical trials in coronary angiogenesis:Issues, problems,consensus an expert panel summary[J].Circulation,2000,102(11):E73-86.
[56] DAmore P A,Thompson R W.Mechanisms of angiogenesis[J].Annu.Rev.Physiol.,1987,49:453-464.
[57] Takabashi M,Fukuda K,Ohata T,et al.Increased expression of inducible and endothelial constitutive nitric oxide synthase in rat colon tumors induced by azoxymethane[J].Cancer Res.,1997,57(7):1233-1237.
[58]黄清玲,郑大利,张声,等.原发性肝癌中结构型一氧化氮合酶mRNA的表达及其意义[J].中华肿瘤杂志,2003,25(3):250-254.
[59] Murohara T, Asahara T, Silver M,et al.Nitric oxide synthase modulates angiogenesis in response to tissue ischemia[J].J.Clin.Invest.,1998,101(11):2567-2578.
[60] Fulton D,Gratton J P, McCabe TJ,et al.Regulation of endothelium-derived nitric oxide production by the protein kinase[J].Akt.Nature,1999,399:597-601.
[61] Ando A,Yang A,Mori K,et al.Nitric oxide is proangiogenic in the retina and choroids[J].J.Cell Physiol,2002,191(1):116-124.
[62] Cooke J P.NO and angiogenesis[J].Atheroscler Suppl,2003,4(4):53-60.
[63] Quan-Sing Ng,Vicky Goh,Jessica Milner,et al.Effect of nitric-oxide synthesis on tumour blood volume and vascular activity:a phase I study[J].The Lancet Oncology,2007,8(2):111-118.
[64] Kimura H,Esumi H.Reciprocal regulation between nitric oxide and vascular endothelial growth factor in angiogenesis[J].Acta Biochimica Polonica,2003,50(1), 49-59.
[65] Shen BQ,Lee DY,Zioncheck TF.Vascular endothelial growth factor governs endotheljal nitric-oxide synthase expression via a KDR/Flk-l receptor and a protein kinase C signaling pathway[J].J Biol Chem,1999,274(46):33057-33063.
[66] Fukumura D,Gohongi T,Kadambi A,et al.Predominant role of endothelial nitric oxide synthase in vascular endotllelial growth factor-induced angiogenesis and vascular permeability[J].Proc Nat Acad Sci USA,200l,98(5):2604-2609.
[67]梁玮,马健.糖尿病[M].赤峰:内蒙古科学技术出版社,2002,1-20.
[68]彭兴.糖尿病保健问答.甘肃科学技术出版社,1996,13-23.
[69] Inzucchi S E.Oral Antihyperglycemic Therapy for Type 2 Diabetes [J]. J.A.M.A. 2002,287,360-372.
[70] Stratton I M,Adler A I,Neil H A W.Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35) : prospective observational study[J].British Medical Journal,2000,321(7258):405-412.
[71] Slchouwer C A D,Fischer H R A,Van K LIiik AW R,et al.Endothelial dysfunction proceeds development of microalbuminuria in IDDM[J].J.Diabetes,995,44:561-564.
[72] Williams S B,Cusco J A,Roddy M A,et al.Inpaired nitric oxide mediated vasodilatation in patients with non-insulin dependent diabetes mellitus[J].J Am Coll Cardiol,l996,27:567-574.
[73] Veves A,Akbari C M,Primavera J,el al.Endothelial dysfunction and the expression of endothelial nitric oxide synthase in diabelic neuropathy.vascuIar disease and food ulceration[J].J Diabetes,1998,47:457-46.
[74] Ginardino J,Fard A K,Hatchell D L,et a1.Aminoguanidine inhibits reactive oxygen species formation,lipid peroxidation,and oxidant-induced apeptosis[J].Diabetes,1998,47,l114-l120.
[75] Pieper G M,Peltier B A.Amelioration et al L-ginine of a dy~functionel argininal nitric oxide pathway in diabetic endothelium[J].J Cardio Pharmaco,1995,25:397-403.
[76] kam oto Sadachi,Kazushi M inam i Yasuharu Niwa,et al.Effect of exercise training and food restruction on endothelium dependent relaxation in the Otsuka Long-Evans Tokoshima Fatty rat.a model of spontanious NIDDM[J].Diabetes,1998,47:82-86。
[77] Morimoto M,Tanimoto K,Nakano S.Insect Antifeedant Activity of Flavones and Chromones against Spodoptera litura[J].J.Agric.Food.Chem.,2003,51(2):389–393.
[78] Bandele O J,Osheroff N.Bioflavonoids as poisons of human topoisomerase IIαand IIβ[J].Biochemistry,2007,46(20):6097-6108.
[79]张德权,台建祥,付勤.生物类黄酮的研究及应用概况[J].食品与发酵工业,1999,25(6):52-57.
[80] Carlo G D,Mascolo N,Lzzo A A,et a1.Flavonoids:old and new aspecs of a class of natural therapeutic drugs[J].Life science,1999,65(4):337-353.
[81] Saija A,Scalese M,Lanza M.Flavonoids as antioxidant agents:Importance of their interaction with biomembranes[J].F.Free.Radical.Biol.Med.,1995,19(4):481-486.
[82]龙海荣,杨洋,刘绍州.黄酮类化合物的安全性研究进展[J].食品研究与开发,2008,29(10):154-157.
[83] EI-Subbagh H I,Abu-Zaid S M,Mahran M A, et al.Synthesis and Biological Evaluation of Certainα,β-Unsaturated Ketones and Their Corresponding Fused Pyridines as Antiviral and Cytotoxic Agents[J].J.Med.Chem.,2000,43(15):2915-2921.
[84] Recanatini M,Bisi A,Cavalli A,et al.A New Class of Nonsteroidal Aromatase Inhibitors:Design and Synthesis of Chromone and Xanthone Derivatives and Inhibition of the P450 Enzymes Aromatase and 17α-Hydroxylase/C17,20-Lyase[J].J.Med.Chem.,2001,44(5):672-680.
[85] Gobbi S,Caralli A,Rampa A,et al.Lead Optimization Providing a Series of Flavone Derivatives as Potent Nonsteroidal Inhibitors of the Cytochrome P450 Aromatase Enzyme [J].J.Med.Chem.,49(15):4777-4780.
[86] Gayot S X,Santarelli,Coulon D.Modification of flvonoid using lipase in non-conventional media:effect of the water content[J].Journal of Biotechnology,2003,101:29-36.
[87] Tanaka T,Kusano R,Kouno I.Synthesis and antioxidant activity of novel amphipathic derivatives of tea polyphenol[J].Bioorga.and Ned.Chem.Lett.,1998,(8):1801-1806.
[88] Spencer J P E,Kuhnle G G C,Williams R J,et a1.Intracellular metabolism and bioactivity of quercetin and its in vivo metabolites[J].Biochem.J.,2003,372:173-l81.
[89] Pericles C,Theofanis G,et a1.Synthesis of inositol-2- phosphate-quercetin conjugates[J]. Carbohydrate Research,1996,292:83-90.
[90]何晓英,贾正平,葛欣.天然植物及中药黄酮类对糖尿病的药理作用[J].医学综述,2003,9(10):629-630.
[91] Lai H H,Yen G C.Inhibitory effect of isoflavones on peroxynitrite-mediated low-density lipoprotein oxidation [J].Biosci Biotechnol Biechem,2002,66(1):22-25.
[92]徐向进,张家庆,黄庆玲.水飞蓟素对糖尿病大鼠主动脉非酶糖化及氧化的抑制作用[J].第二军医大学学报,1997,l8(1):59-62.
[93] Lean M E,Noroozi M,Kelly I,et a1.Dietary flavonols protect diabetic human lymphocytes against oxidative damage to DNA[J].Diabetes,1999,8(1):176-178.
[94]李家富,李红辉,何涛.槲皮素对实验性糖尿病大鼠心肌的保护作用[J].泸州医学院学报,1999,22(2):102-104.
[95]江清林,李延君,辛华,等.黄芪甲甙对胰岛素C肽分泌作用研究[J].黑龙江医药科学,1999,22(3):9-11.
[96] Chen F,Nakeshima N,Kimura I,et al.Hypoglycemic activity and mechanisms of extracts from mulberry leaves (folium moil)and codex mori radicis in streptozotocin-induced diabetic mice[J].Yakugaku Zasshi,1995,115(6):476-479.
[97]刘长山,陈惠黎,查锡良,等.4种药物对全糖还原酶的抑制作用[J].上海医科大学学报,1996,24(6):433-435.
[98] Kim J S,Kwon C S,Son K H.Inhibition of alpha-glucosidase and amylase by luteolin,a flavonoid[J].Biosci. Biotechnol. Biochem.,2000,64(11):2458-2460.
[99] Valensi P E,Behar A,Champvallius M M,et al.Efects of a purified micronized flavonoid fraction on capillary filtration in diabetic patents[J].Diabet Med,1996,13(10):882-884.
[100] Grassmann J,Hippeli S,Elstner E F.Plant’s defence and its benefits for animals and medicine:role of phenolics and terpenoids in avoiding oxygen stress[J] . Plant Physiology and Biochemistry,2002,40(6-8):471-478.
[101] Wolfman C,Viola H,Paladini A,et al.Possible anxiolytic effects of chrysin,a central benzodiazepine receptor ligand isolated from Passiflora coerulea[J]. Pharmacology biochemistry and behavior,1994,47(1):1-4.
[102] Xu H X,Lee S F.Activity of plant flavonoids against antibiotic-resistant bacteria[J]. Phytotherapy Research,2001,15(1):39-43.
[103] Birt D F,Hendrich S,Wang W.Dietary agents in cancer prevention:flavonoids and isoflavonoids[J].Pharmacol.Therap.,2001,90:157-177.
[104] Pérez-Vizcaíno F,Ibarra M,Cogolludo A L. Endothelium-Independent Vasodilator Effects of the Flavonoid Quercetin and Its Methylated Metabolites in Rat Conductance and Resistance Arteries[J].Journal of Pharmacology and Experimental Therapeutics,2002,302(1):66-72.
[105] Ae E A,Han M J,Lee M,et al.Inhibitory Effect of Some Flavonoids on Rotavirus Infectivity[J].Biological and Pharmaceutical Bulletin,2000,23(9):1122-1124.
[106]李发荣,张尊听,陈莉莉,等.6,8-二羟甲基白杨素和6,8-二羟甲基醚白杨素及其制备方法与药物用途[P].中国:200710017327.X.公开日期
[107]张尊听,陈莉莉.白杨素衍生物的合成和晶体结构及与DNA的作用[J].药学学报,2007,42(5):492-496.
[108] Suresh B K.Synthesis and biological evaluation of novel C (7) modified chrysin analogues as antibacterial agents[J].Bioorganic & Medicinal Chemistry Letters,2006,16:221-224.
[109] Park H,Dao T T,Kim H P.Synthesis and inhibition of PGE2 production of 6,8-disubstituted chrysin derivatives[J].European Journal of Medicinal Chemistry,2005,40(9):943-948.
[110] Mentzer C,Massicot J.Hydrogen-transfer reactions in the flavones[J]. Bull. Soc. Chim. France,1956,144-148.
[111]程永浩,段亚波.松属素的均匀优化设计法合成研究[J].化学研究与应用,2006,18(11):1334-1335.
[112] Auffret G, Labaied M, Frappier F.et al. Synthesis and antimalarial evaluation of a series of piperazinyl flavones[J],Bioorganic & Medicinal Chemistry Letters,2007,17(4):959-963.
[113] Daskiewicz J B,Depeint F,Viornery L,et al.Effects of Flavonoids on Cell Proliferation and Caspase Activation in a Human Colonic Cell Line HT29:An SAR Study[J].Journal of Medicinal Chemistry,2005,48(8):2790-2804.
[114] Xing Zheng,Wei-Dong Meng,Yang-Yan Xu,et a1.Synthesis and anticancer effect of chrysin derivatives[J].Bioorganic & Medicinal Chemistry Letters,2003,13(5):881-884.
[115]邹晓青,郑兴,曹建国,等.6,8-二一三氟甲基-5-羟基-7-乙酰基白杨素的抗肿瘤作用[J].中国药理学通报,2004,20(4):453-457.
[116]尚思异,杨林,郑兴,等.8-溴-7-甲氧基白杨素的合成及其抗人急性细胞性白血病作用[J].美国中华临床医学杂志,2004,6(2):87-89.
[117] Zheng X,Meng W D,Qing F L,et al.Synthsis and anticancer effect of chrysin derivatives[J]. Bioorg.Med.Chem.Lett.,2003,13 (5):881-884.
[118]徐阳炎,郑兴,朱炳阳,等.8-硝基白杨素的合成及其抗肿瘤作用[J].南华大学学报(医学版),2004,32(3):283-286.
[119]康颖,郑兴,徐阳炎,等.7-二氟亚甲基-5-取代烷氧基黄酮类化合物的合成及其对人胃癌细胞增殖的抑制作用[J].美国中华临床医学杂志,2006,8(1):63-65,81.
[120] Comte G,Daskiewicz J B,Bayet C,et al.C-Isoprenylation of Flavonoids Enhances Binding Affinity toward P-Glycoprotein and Modulation of Cancer Cell Chemoresistance [J]. J.Med.Chem.,200l,44(5):763-768.
[121] Uhl M,Ecker S,Kassie F,et al.Effect of chrysin,a flavonoid compound,on the mutagenic activity of 2-amino-l-methyl-6-phenylimidazo(4,5-b) pyridine (PhIP)and benzo(a)pyrene(B(a)P) in bacterial and human hepatoma (HepG2)cells[J].Arch toxicol,2003,77(8):477-484.
[122] Gao H,Kawabata J.α-Glucosidase inhibition of 6-hydroxyflavones.Part 3: Synthesis and evaluation of 2,3,4-trihydroxybenzoyl-containing flavonoid analogs and 6-aminoflavones as a-glucosidase inhibitors[J].Bioorganic & Medicinal Chemistry,2005,13:1661-1671.
[123] Shin J S,Kim K S,Kim M B,et al.Synthesis and hypoglycemic effect of chrysin derivatives[J].Bioorganic & Medicinal Chemistry Letter,1999,9(6):869-874.
[124] Parenti A.Nitric oxide is an upstream signal of vascular endothelial growth factor-induced extracellular signal-regulated kinasel/2 activation in postcapillary endothelium[J].J.Biol.Chem.,l998,273:4220-4226.
[125] Fulton D,Gratton J P.McCab e TJ,et al.Regulation of endothelium-derived nitric oxide production hy the protein kinase Akt[J].Nature,1999,399:597-601.
[126] Wang J P, Shang Fujun, Jiang Ru, et al. Nitric oxide-donating genistein prodrug: Design, synthesis, and bioactivity on MC3T3-E1 cells[J], Journal of pharmacological sciences,2007, 104:82-89.
[127] Shin J S, Kim K S, Kim M B, et al. Synthesis and hypoglycemic effect of chrysin derivatives[J], Bioorganic & Medicinal Chemistry Letter, 1999, 9(6): 869-874.
[128] Suresh Babu K, Synthesis and biological evaluation of novel C (7) modified chrysin analogues as antibacterial agents[J], Bioorganic & Medicinal Chemistry Letters,2006,16: 221-224.
[129]于小凤,孙茂春,白雪洁等, NO供体黄酮类化合物的合成及生物活性研究.中国药物化学杂志[J], 2005,15(4):197-201.
[130] Gasco A M, Frutter R, Sorba G, et al. Phenylfuroxancarbaldehydes and related compounds[J], Liebigs Annalen der Chemie,1991,1111-1211.
[131] Sorba G, Medana C, Fruttero R, et al.Water soluble furoxan derivatives as NO prodrugs[J], J. Med. Chem, 1997,40: 463-469.
[132] Renodon-Comiere A,Dijols S,Perollier C,et a1.N-Aryl-N'-hydroxy guanidines, a new class of NO-donors after selective oxidation by nitric oxide synthases:structure-activity relationship[J].J Med Chem,2002,45(4):944-954.
[133]石卫兵,王未东,赖宜生,等.一氧化氮供体N-芳基-N′-羟基胍类化合物的合成[J].药学进展, 2005, 29 (11: 508-511.
[134] Aoki M, Preparation of carbonic acid esters of 2-hydroxyguanidines as intrmediates for dyes, photographic couplers, drugs, and pesticides[ P]. JP 2001316350A2, 2001.11.13
[135] Madar Z, Omunsky Z. Inhibition of intestinalα-glucosidase activity and postpradial hyperglycemia byα-glucosidase inhibitors in fa/fa rats[J]. Nutr. Res., 1991, 11, 1035-1046.
[136] DeBouno J F, Michaelis O E, et al.. The effects of the intestinal glucosidase inhibitor Bay M 1099(miglitol) on glycemic status of obese-diabetic rats[J]. Gen. Pharamic., 1993, 24: 509-515.。
[137] Saul R, Chambers J P, Molyneux R J, et al.. Castanospermine, a Tetrahydroxylated Alkaloid that Inhibits beta-Glucosidase and beta-Glucocerrebrosidase[J]. Archives of Biochemistry and Biophysics. 1983, 221(2): 593-597.
[138] Atsumi S, Kazuo Umezawa, et al.. Production, isolation and structure determination of a novelβ-Glucosidase and inhibitor,cyclophellitol[J]. The Journal of Antibiotics, 1990, 43(1): 49-53.
[139] Kurihara H, Masayoshi Sasaki, et al.. A New Screening Method for Glucosidase Inhibitors and its Application to Algal Extracts[J]. Fisheries Science, 1994, 60(6): 759-761.。Part A Anat Re., 2001,264(4):317-324
[140] Mosmann T. Rapid Colorimetric assay for cellular growth and survival; application to proliferation and cytotoxicity assays. J Immuno Medthods,1983,65(1-2):55-63Journal of Immunological Methods Volume 65, Issues 1-2, 16 December 1983, Pages 55-63
[141] Bootle-Wilbraham C A, Tazzyman S, Thompson W D, et a1.Fibrin fragment E stimulates the proliferation, migration and differentiation of human microvascular endothelial cells in vitro [J].Angiogenesis,2001,4(4):269-275
[142] Domenico Ribatti, Beatrice Nico, Angelo Vacca , et a1.Chorioallantoic membrane capillary bed: A useful target for studying angiogenesis and anti-angiogenesis in vivo [J].The Anatomical Record Part A Anat Re., 2001,264(4):317-324
[143] Thompson T W D, Reid A.Quantitative assays for the chick chorioallantoic membrane [J]. Adv Exp Med Biol, 2000,476:225-229.
[144] Liu J M, Lawrence F, Kovacevic M, Bignon J, Papadimitriou E, Lallemand J Y, Katsoris P, Potier P, Fromes Y, et al. The tetrapeptide AcSDKP, an inhibitor of primitive hematopoietic cell proliferation, induces angiogenesis in vitro and in vivo[J]. Blood , 2003, 101(8): 3014-3020.
[145] Yan X, Lin Y, Yang D, et al. A novel anti-CD146 monoclonal antibody, AA98, inhibits angiogenesis and tumor growth[J]. Blood, 2003, 102(1): 184-191.
[146] Vacca A, Ribatti D, Presta M, et al. Bone marrow neovascularization, plasma cell angiogenic potential, and matrix metalloproteinase-2 secretion parallel progression of human multiple myeloma[J]. Blood,1999, 93(9): 3064-3073.
[147] Strick D M,Waycaster R L,Montani J P,et a1.Morphometric measurements of chorioallantoic membrane vascularity:effects of hypoxia and hyperoxia[J].Am J Physiol,1991,260(4 Pt 2):1 385-1389.
[148] Santulli R J, Kinney W A, et al. Studies with an orally bioavailable alpha V integrin antagonist in animal models of ocular vasculopathy: retinal neovascularization in mice and retinal vascular permeability in diabetic rats[J]. J Pharmacol Exp Ther 2008 324(3): 894-901.
[149]] Colman R W, Jameson B A, Lin Y, et al. Domain 5 of high molecular weight kininogen (kininostatin) down-regulates endothelial cell proliferation and migration and inhibits angiogenesis[J]. Blood, 2000, 95(2): 543-550.
[150] Dusseau J W, Hutchins P M and Malbasa D S, et al. Stimulation of angiogenesis by adenosine on the chick chorioallantoic membrane[J].Circulation Research. 1986; 59: 163-170.
[151] Wu G Y, Brosnan J T , Macrophages can convert citrulline into arginine[J], Biochem J, 1992, 281(1): 45-48.
[152] Verdon C P, Burton B A, Prior R L, et a1. Sample pretreatment with nitrate reductase and glucose-6-phosphate dehydrogenase quantitatively reduces nitrate while avoiding interference by NADP+ when the Griess reaction is used to assay for nitrite[J], Anal Biochem,1995,1224:502-508.
[153] Archer S. Measurement of nitric oxide in biological models[J], The FASEB Journal, 1993, 7: 349-360.
[2] Robert W,Mcpherson,Jeffrey R,et a1.Effect of nitric oxide synthase inhibition on the cerebral vascular response to hypercapnia in primates.Stroke,1995,26:682-687.
[3] Faraci F M,Brian J E.Nitric oxide and the cerebral circulation[J].Stroke,1994,25:692-703.
[4] Bredt D S,Snyder S H.Nitric:A physiologic messenger molecuiar[J].Annual Review of Biochemistry,1994,63:175-195.
[5]张忠.一氧化氮与脑循环[J].国外医学-内科学分册,1996,23(8):337-339.
[6] Ziche M,Morbidelli L,Masini E,et al.Nitric oxide mediates angiogenesis in vivo and endothelial cell growth and migration in vitro promoted by substance[J].J Clin Invest l994,94:2036-2044.
[7] Wilkinson-Berka J L.Vasoactive factors and diabetic retinopathy:vascular endothelia growth factor,cycoloxygenase-2 and nitric oxide[J].Curr Pha Des,2004,10(27):333l-3348.
[8]伍欣星,聂广.医学分子生物学原理与方法[M].北京:科学出版杜,2000,267-269.
[9] Myers P R,Minor R L,G uerraR,et al.Vasorelaxant properties of the endothelium- derived relaxing factor more closely resemble S–nitrosocysteine than nitric oxide[J].Nature,1990,345:161-163.
[10] Rosenblum W I.Endothelium-derived relaxing factor in rain blood vessels is not nitric oxide[J].stroke,1992,23:1527-1532.
[11] Moncada S,Higgs A,Fuchgott F R.International union of pharmacology nomenclature in nitric oxide research[J].Pharmacol Rev,1997,49:137-142.
[12] Faraci F M,Heistad D D.Regulation of the cerebral circulation:role of endothelium and potassium channels[J].Physiol Rev,1998,78(1):53-97.
[13] Megson I L.Nitric oxide donor drugs[J].Drugs of the Future,2000,25(7):70l-705.
[14] Searena R,Bottoni P,Martorana G E,et al.Nitric oxide donor drugs:an update on pathophysiology and therapeutic potential[J].Expert Opinion on Investigational Drugs,2005,14(7):835-846.
[15] Roberts J D,Polaner D M,Lang P,et al.Inhaled nitrico xide in persistent pulmonary hypertension of the newborn[J].Lancet,1992,340:818-819.
[16] Kinsella J P,Neish S R,Shaffer E,et al.Low-dose inhala-tional nitricoxide in persistent pulmonary hypertension of the newborn[J].Lancet,1992,340:819-820.
[17] Feelisch M.The biochemical pathways of nitric oxide formation from nitrovasodilators:appropriate choice of exogenous NO donors and a spects of preparation and handling of aqueous NO solutions[J].Journal of Cardiovascular Pharmacology,1991,17(Suppi.3):S 25-S33.
[18] Stamler J S, Singel D J, Loscalzo J.Biochemistry of nitric oxide and its redox- activated forms[J].Science,1992,258:1898-1902.
[19] Hou Y C,Janczuk A,Wang P G.Current trends in the development of nitric oxide donors[J].Current pharmaceutical design,1999,5(6):417-441.
[20] Wang P C,Xian M,Tang X,et al.Nitric oxide donors and biological applications[J]. Chem. Rev. ,2002,102(4):1091-1134.
[21] Cirino G.Nitric oxide releasing drugs:from bench to bedside[J].Digestive and Liver Disease,2003,35(Suppl 2):2-8.
[22]李松,陈畅,史艳秋,等.一氧化氮供体最新研究进展及应用前景[J].中国生化药物杂志,2006,27(6):374-379.
[23] Wallce J L,McknJight W,Wilson TL,et al.Reduction of shock-induced gastric damage by a nitric oxide-releasing aspirin derivative:role of neutrophils[J].American Journal of Physiology,1997,273(6):l246-l252.
[24] Li Y Q, Ji H, Zhang Y H,et al.A novel nitric oxide-releasing derivative of elm-isartan,inhibits hypertension and improves glucose metabolism in rats[J].European Journal of Pharmacology,2007,1-3(577):100-108.
[25] Wang H K,Xia Y,Yang ZY,et al.Recent advances in the discovery and development of flavonoids and their analogues as antitumor and anti-HIV agents[J]. Adv. Exp. Med. Biol.,1998,439:191-225.
[26]陈莉,张奕华.前药原理在非甾体抗炎药中的应用[J].中国药师,2003,6(1):50-52.
[27] Bandarage U K,Chen L,Fang X,et a1.Nitrosothiol esters of diclofenac:synthesis and pharmacological characterization as gastrointestinal-sparing prodrugs[J]. J. Med. Chem.,2000,43(21):4005-4016.
[28] De Tejada I S,Garvey D S,Sehroeder J D,et a1.Design and evaluation of nitrosylated alpha-adrenergic receptor antagonists a potential agents for the treatment of impotence[J].J.Pharmaeol.Exp.Ther.,1999,290(I):121-128.
[29] Whittle B R J.Temporal relationship between cycloxygenase inhibition,as measured by prostaglandin biosynthesis,and the gastrointestinal damage induced by indomethacin in the rat[J].Gastroenterology,1981,80:94-98.
[30] Lechi C,Andrioli G,Guino S,et al.The antiplatelet effects of a new nitroderivative of acetylsalicylic acid- an in vitro study of inhibition on the early phase of platelet activation and on TXA2 proltuction[J].Thromb Haemost,1996,76(5):791-798.
[31] Wallace J L,Muscara M N,McKnight W,et a1.In vivo antithrombotie effects of a nitric oxide-releasing aspirin derivative,NCX-4016[J],Thromb.Res.,1999,93(1):43-50.
[32] Wallace J L,Vergnolle N,Muscara M N, et a1.Enhanced anti-inflammatory effects of a nitri oxide-releasing derivative of mesalamine in rats[J], Gastroenterology,1999,117(3):557-566.
[33] Paul-Clark M,Del Soldato P,Fiorucci S,et al.21-NO-prednisolone is a novel nitric oxide-releasing derivative of prednisolone with enhanced anti- inflammatory properties[J].Br.J.Pharmacol.,2000,131(7):1345-1354.
[34] Ricardo de L B,Carlos Roque D C,Marcelo N M, Nitric oxide:properties and therapeutic use[J].Química Nova,2005,28(6):1046-1054.
[35] Endres S,HackerA,Noack E,et a1.NO-Donors,part 3:nitrooxyacylated thiosalicylates and salicylates synthesis and biological aetivities[J].Eur.J.Med.Chem.,1999,34(11):895-901.
[36] Ricardo de L B,Carlos Roque D C,Marcelo N M.Nitric oxide:properties and therapeutic use[J].Química Nova,2005,28(6):1046-1054.
[37] Lehmann J,Kahlich R,Meyer zum Gottesberge C,el al. Organic nitrates.II.Synthesis and biological activities of 4-nitrooxymethylphenyl 1,4-dihydropyridines[J]. Arch.Pharm.,1997,330(8):247-252.
[38] Haj-Yetlla A,Nassar T,Lntan C,et a1.Development of 3-nitratomethyl-proxyl (NMP):a novel,bifunctional superoxide dismutase-mimic-nitricoxide-donor [J].Drug.Dev.Res.,2000,50(3-4):528-536.
[39] Fruttero R,Boschi D,Di Stilo A,et a1.Tile furoxan system as a useful tool for balancing“hybrids”with mixed alpha 1-antagonist and NO-like vasodilator activitiesl [J].J.Med.Chem.,1995,38(25):4944-4949.
[40] Di Stilo A,Viscntin S,Cena C,et a1.NO donor and biological properties of different benzofuroxans endowed with both nitric oxide-1ike and calcium channel antagonist vasodilator activities[J].J.Med.Chem.,1998,41(27):5393-5401.
[41] Visentin S,Amiel P,Frultero R,et al.Synthesis and voltage-clamp studies of methyl 1,4-dihydro-2 , 6-dimethyl-5-nitro-4-(benzofurazany1) pyridine -3-carhoxylate racemates and enanliomers and of their benzofuroxanyl analogues[J]. J. Med. Chem.,1999,42(8):1422-1427.
[42] Mu L,Feng S S,Go M I.A Study of synthesis and cardiovascular activity of some furoxan derivatives as potential NO-donors[J].Chem.Pharm.Bull.,2000,48(6):808-816.
[43] Saavedra J E,Shami P J,Wang I Y,et a1, Esterase-sensitive nitric oxide donors of the diazeniumdiolate family in vitro antileukemic activity[J],J Med Chem,2000,43(2):261-269.
[44] Hou Yongchun,Xie Wenhua,Wang Peng George,et a1.O-Alkylation of cupferron:aiming at the design and synthesis of controlled nitric oxide releasing agents[J]. J.Org.Chem.,2000,65(14):4333-4337.
[45] Tang Xiaoping,Xian Ming,Wang Peng George,et a1.Synitlesis of peptide- diazeniumdiolate conjugate:towards enzyme activated antitumor agents[J]. Tetrahedron Lett.,2001,42:2625-2629.
[46] Wu Xuejun,Tang Xiaoping,Wang Peng George,et a1.Glyeosylated diazeniumdiolates:anovel class of enzyme-activated nitric oxide donors [J]. Tetrahedron Lett.,2001,42:3779-3782.
[47] Risau W.Mechanisms of angiogenesis[J].Nature,1997,386:671-674.
[48] Hershey J C,BaskinE P,Glass J D,et a1.Revascularization in the rabbit hindlimb:dissociation between capillary sprouting and arteriogenesis[J].Cardiovasc Res,2001,49:618-625.
[49] Risau W.Mechanisms of angiogenesis[J].Nature,1997,386:671-674.
[50] Folkman J.Angiogenesiain cancer,vascular,rheumatoid and other disease[J]. Nat. Med. ,1995,l(1):27-31.
[51]卞修武,史景泉.血管内皮生长因子及其受体在肿瘤血管生成中的作用与抗血管生成研究进展[J].中华病理学杂志,1997,26(4):248-250.
[52] Bian X W,Du L L,Shi J Q.Correlation of bFGF,FGFR-1 and VEGF expression with vascularity and malignancy of human astrocytomas[J].Analyt Quant Cytol Histo1,2000,22(3):267-274.
[53]孙慧勤,邹仲敏,卞修武,等.正常血管和肿瘤血管生成的调节机制研究进展[J].中华病理学杂志,2000,29(3):224-226.
[54] Fidler I J.Angiogenesis and cancer metastasis[J].Cancer J.,2000,(suppl2): 134-141.
[55] Simons M,Bonow R O,Chronos N A,et al.Clinical trials in coronary angiogenesis:Issues, problems,consensus an expert panel summary[J].Circulation,2000,102(11):E73-86.
[56] DAmore P A,Thompson R W.Mechanisms of angiogenesis[J].Annu.Rev.Physiol.,1987,49:453-464.
[57] Takabashi M,Fukuda K,Ohata T,et al.Increased expression of inducible and endothelial constitutive nitric oxide synthase in rat colon tumors induced by azoxymethane[J].Cancer Res.,1997,57(7):1233-1237.
[58]黄清玲,郑大利,张声,等.原发性肝癌中结构型一氧化氮合酶mRNA的表达及其意义[J].中华肿瘤杂志,2003,25(3):250-254.
[59] Murohara T, Asahara T, Silver M,et al.Nitric oxide synthase modulates angiogenesis in response to tissue ischemia[J].J.Clin.Invest.,1998,101(11):2567-2578.
[60] Fulton D,Gratton J P, McCabe TJ,et al.Regulation of endothelium-derived nitric oxide production by the protein kinase[J].Akt.Nature,1999,399:597-601.
[61] Ando A,Yang A,Mori K,et al.Nitric oxide is proangiogenic in the retina and choroids[J].J.Cell Physiol,2002,191(1):116-124.
[62] Cooke J P.NO and angiogenesis[J].Atheroscler Suppl,2003,4(4):53-60.
[63] Quan-Sing Ng,Vicky Goh,Jessica Milner,et al.Effect of nitric-oxide synthesis on tumour blood volume and vascular activity:a phase I study[J].The Lancet Oncology,2007,8(2):111-118.
[64] Kimura H,Esumi H.Reciprocal regulation between nitric oxide and vascular endothelial growth factor in angiogenesis[J].Acta Biochimica Polonica,2003,50(1), 49-59.
[65] Shen BQ,Lee DY,Zioncheck TF.Vascular endothelial growth factor governs endotheljal nitric-oxide synthase expression via a KDR/Flk-l receptor and a protein kinase C signaling pathway[J].J Biol Chem,1999,274(46):33057-33063.
[66] Fukumura D,Gohongi T,Kadambi A,et al.Predominant role of endothelial nitric oxide synthase in vascular endotllelial growth factor-induced angiogenesis and vascular permeability[J].Proc Nat Acad Sci USA,200l,98(5):2604-2609.
[67]梁玮,马健.糖尿病[M].赤峰:内蒙古科学技术出版社,2002,1-20.
[68]彭兴.糖尿病保健问答.甘肃科学技术出版社,1996,13-23.
[69] Inzucchi S E.Oral Antihyperglycemic Therapy for Type 2 Diabetes [J]. J.A.M.A. 2002,287,360-372.
[70] Stratton I M,Adler A I,Neil H A W.Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35) : prospective observational study[J].British Medical Journal,2000,321(7258):405-412.
[71] Slchouwer C A D,Fischer H R A,Van K LIiik AW R,et al.Endothelial dysfunction proceeds development of microalbuminuria in IDDM[J].J.Diabetes,995,44:561-564.
[72] Williams S B,Cusco J A,Roddy M A,et al.Inpaired nitric oxide mediated vasodilatation in patients with non-insulin dependent diabetes mellitus[J].J Am Coll Cardiol,l996,27:567-574.
[73] Veves A,Akbari C M,Primavera J,el al.Endothelial dysfunction and the expression of endothelial nitric oxide synthase in diabelic neuropathy.vascuIar disease and food ulceration[J].J Diabetes,1998,47:457-46.
[74] Ginardino J,Fard A K,Hatchell D L,et a1.Aminoguanidine inhibits reactive oxygen species formation,lipid peroxidation,and oxidant-induced apeptosis[J].Diabetes,1998,47,l114-l120.
[75] Pieper G M,Peltier B A.Amelioration et al L-ginine of a dy~functionel argininal nitric oxide pathway in diabetic endothelium[J].J Cardio Pharmaco,1995,25:397-403.
[76] kam oto Sadachi,Kazushi M inam i Yasuharu Niwa,et al.Effect of exercise training and food restruction on endothelium dependent relaxation in the Otsuka Long-Evans Tokoshima Fatty rat.a model of spontanious NIDDM[J].Diabetes,1998,47:82-86。
[77] Morimoto M,Tanimoto K,Nakano S.Insect Antifeedant Activity of Flavones and Chromones against Spodoptera litura[J].J.Agric.Food.Chem.,2003,51(2):389–393.
[78] Bandele O J,Osheroff N.Bioflavonoids as poisons of human topoisomerase IIαand IIβ[J].Biochemistry,2007,46(20):6097-6108.
[79]张德权,台建祥,付勤.生物类黄酮的研究及应用概况[J].食品与发酵工业,1999,25(6):52-57.
[80] Carlo G D,Mascolo N,Lzzo A A,et a1.Flavonoids:old and new aspecs of a class of natural therapeutic drugs[J].Life science,1999,65(4):337-353.
[81] Saija A,Scalese M,Lanza M.Flavonoids as antioxidant agents:Importance of their interaction with biomembranes[J].F.Free.Radical.Biol.Med.,1995,19(4):481-486.
[82]龙海荣,杨洋,刘绍州.黄酮类化合物的安全性研究进展[J].食品研究与开发,2008,29(10):154-157.
[83] EI-Subbagh H I,Abu-Zaid S M,Mahran M A, et al.Synthesis and Biological Evaluation of Certainα,β-Unsaturated Ketones and Their Corresponding Fused Pyridines as Antiviral and Cytotoxic Agents[J].J.Med.Chem.,2000,43(15):2915-2921.
[84] Recanatini M,Bisi A,Cavalli A,et al.A New Class of Nonsteroidal Aromatase Inhibitors:Design and Synthesis of Chromone and Xanthone Derivatives and Inhibition of the P450 Enzymes Aromatase and 17α-Hydroxylase/C17,20-Lyase[J].J.Med.Chem.,2001,44(5):672-680.
[85] Gobbi S,Caralli A,Rampa A,et al.Lead Optimization Providing a Series of Flavone Derivatives as Potent Nonsteroidal Inhibitors of the Cytochrome P450 Aromatase Enzyme [J].J.Med.Chem.,49(15):4777-4780.
[86] Gayot S X,Santarelli,Coulon D.Modification of flvonoid using lipase in non-conventional media:effect of the water content[J].Journal of Biotechnology,2003,101:29-36.
[87] Tanaka T,Kusano R,Kouno I.Synthesis and antioxidant activity of novel amphipathic derivatives of tea polyphenol[J].Bioorga.and Ned.Chem.Lett.,1998,(8):1801-1806.
[88] Spencer J P E,Kuhnle G G C,Williams R J,et a1.Intracellular metabolism and bioactivity of quercetin and its in vivo metabolites[J].Biochem.J.,2003,372:173-l81.
[89] Pericles C,Theofanis G,et a1.Synthesis of inositol-2- phosphate-quercetin conjugates[J]. Carbohydrate Research,1996,292:83-90.
[90]何晓英,贾正平,葛欣.天然植物及中药黄酮类对糖尿病的药理作用[J].医学综述,2003,9(10):629-630.
[91] Lai H H,Yen G C.Inhibitory effect of isoflavones on peroxynitrite-mediated low-density lipoprotein oxidation [J].Biosci Biotechnol Biechem,2002,66(1):22-25.
[92]徐向进,张家庆,黄庆玲.水飞蓟素对糖尿病大鼠主动脉非酶糖化及氧化的抑制作用[J].第二军医大学学报,1997,l8(1):59-62.
[93] Lean M E,Noroozi M,Kelly I,et a1.Dietary flavonols protect diabetic human lymphocytes against oxidative damage to DNA[J].Diabetes,1999,8(1):176-178.
[94]李家富,李红辉,何涛.槲皮素对实验性糖尿病大鼠心肌的保护作用[J].泸州医学院学报,1999,22(2):102-104.
[95]江清林,李延君,辛华,等.黄芪甲甙对胰岛素C肽分泌作用研究[J].黑龙江医药科学,1999,22(3):9-11.
[96] Chen F,Nakeshima N,Kimura I,et al.Hypoglycemic activity and mechanisms of extracts from mulberry leaves (folium moil)and codex mori radicis in streptozotocin-induced diabetic mice[J].Yakugaku Zasshi,1995,115(6):476-479.
[97]刘长山,陈惠黎,查锡良,等.4种药物对全糖还原酶的抑制作用[J].上海医科大学学报,1996,24(6):433-435.
[98] Kim J S,Kwon C S,Son K H.Inhibition of alpha-glucosidase and amylase by luteolin,a flavonoid[J].Biosci. Biotechnol. Biochem.,2000,64(11):2458-2460.
[99] Valensi P E,Behar A,Champvallius M M,et al.Efects of a purified micronized flavonoid fraction on capillary filtration in diabetic patents[J].Diabet Med,1996,13(10):882-884.
[100] Grassmann J,Hippeli S,Elstner E F.Plant’s defence and its benefits for animals and medicine:role of phenolics and terpenoids in avoiding oxygen stress[J] . Plant Physiology and Biochemistry,2002,40(6-8):471-478.
[101] Wolfman C,Viola H,Paladini A,et al.Possible anxiolytic effects of chrysin,a central benzodiazepine receptor ligand isolated from Passiflora coerulea[J]. Pharmacology biochemistry and behavior,1994,47(1):1-4.
[102] Xu H X,Lee S F.Activity of plant flavonoids against antibiotic-resistant bacteria[J]. Phytotherapy Research,2001,15(1):39-43.
[103] Birt D F,Hendrich S,Wang W.Dietary agents in cancer prevention:flavonoids and isoflavonoids[J].Pharmacol.Therap.,2001,90:157-177.
[104] Pérez-Vizcaíno F,Ibarra M,Cogolludo A L. Endothelium-Independent Vasodilator Effects of the Flavonoid Quercetin and Its Methylated Metabolites in Rat Conductance and Resistance Arteries[J].Journal of Pharmacology and Experimental Therapeutics,2002,302(1):66-72.
[105] Ae E A,Han M J,Lee M,et al.Inhibitory Effect of Some Flavonoids on Rotavirus Infectivity[J].Biological and Pharmaceutical Bulletin,2000,23(9):1122-1124.
[106]李发荣,张尊听,陈莉莉,等.6,8-二羟甲基白杨素和6,8-二羟甲基醚白杨素及其制备方法与药物用途[P].中国:200710017327.X.公开日期
[107]张尊听,陈莉莉.白杨素衍生物的合成和晶体结构及与DNA的作用[J].药学学报,2007,42(5):492-496.
[108] Suresh B K.Synthesis and biological evaluation of novel C (7) modified chrysin analogues as antibacterial agents[J].Bioorganic & Medicinal Chemistry Letters,2006,16:221-224.
[109] Park H,Dao T T,Kim H P.Synthesis and inhibition of PGE2 production of 6,8-disubstituted chrysin derivatives[J].European Journal of Medicinal Chemistry,2005,40(9):943-948.
[110] Mentzer C,Massicot J.Hydrogen-transfer reactions in the flavones[J]. Bull. Soc. Chim. France,1956,144-148.
[111]程永浩,段亚波.松属素的均匀优化设计法合成研究[J].化学研究与应用,2006,18(11):1334-1335.
[112] Auffret G, Labaied M, Frappier F.et al. Synthesis and antimalarial evaluation of a series of piperazinyl flavones[J],Bioorganic & Medicinal Chemistry Letters,2007,17(4):959-963.
[113] Daskiewicz J B,Depeint F,Viornery L,et al.Effects of Flavonoids on Cell Proliferation and Caspase Activation in a Human Colonic Cell Line HT29:An SAR Study[J].Journal of Medicinal Chemistry,2005,48(8):2790-2804.
[114] Xing Zheng,Wei-Dong Meng,Yang-Yan Xu,et a1.Synthesis and anticancer effect of chrysin derivatives[J].Bioorganic & Medicinal Chemistry Letters,2003,13(5):881-884.
[115]邹晓青,郑兴,曹建国,等.6,8-二一三氟甲基-5-羟基-7-乙酰基白杨素的抗肿瘤作用[J].中国药理学通报,2004,20(4):453-457.
[116]尚思异,杨林,郑兴,等.8-溴-7-甲氧基白杨素的合成及其抗人急性细胞性白血病作用[J].美国中华临床医学杂志,2004,6(2):87-89.
[117] Zheng X,Meng W D,Qing F L,et al.Synthsis and anticancer effect of chrysin derivatives[J]. Bioorg.Med.Chem.Lett.,2003,13 (5):881-884.
[118]徐阳炎,郑兴,朱炳阳,等.8-硝基白杨素的合成及其抗肿瘤作用[J].南华大学学报(医学版),2004,32(3):283-286.
[119]康颖,郑兴,徐阳炎,等.7-二氟亚甲基-5-取代烷氧基黄酮类化合物的合成及其对人胃癌细胞增殖的抑制作用[J].美国中华临床医学杂志,2006,8(1):63-65,81.
[120] Comte G,Daskiewicz J B,Bayet C,et al.C-Isoprenylation of Flavonoids Enhances Binding Affinity toward P-Glycoprotein and Modulation of Cancer Cell Chemoresistance [J]. J.Med.Chem.,200l,44(5):763-768.
[121] Uhl M,Ecker S,Kassie F,et al.Effect of chrysin,a flavonoid compound,on the mutagenic activity of 2-amino-l-methyl-6-phenylimidazo(4,5-b) pyridine (PhIP)and benzo(a)pyrene(B(a)P) in bacterial and human hepatoma (HepG2)cells[J].Arch toxicol,2003,77(8):477-484.
[122] Gao H,Kawabata J.α-Glucosidase inhibition of 6-hydroxyflavones.Part 3: Synthesis and evaluation of 2,3,4-trihydroxybenzoyl-containing flavonoid analogs and 6-aminoflavones as a-glucosidase inhibitors[J].Bioorganic & Medicinal Chemistry,2005,13:1661-1671.
[123] Shin J S,Kim K S,Kim M B,et al.Synthesis and hypoglycemic effect of chrysin derivatives[J].Bioorganic & Medicinal Chemistry Letter,1999,9(6):869-874.
[124] Parenti A.Nitric oxide is an upstream signal of vascular endothelial growth factor-induced extracellular signal-regulated kinasel/2 activation in postcapillary endothelium[J].J.Biol.Chem.,l998,273:4220-4226.
[125] Fulton D,Gratton J P.McCab e TJ,et al.Regulation of endothelium-derived nitric oxide production hy the protein kinase Akt[J].Nature,1999,399:597-601.
[126] Wang J P, Shang Fujun, Jiang Ru, et al. Nitric oxide-donating genistein prodrug: Design, synthesis, and bioactivity on MC3T3-E1 cells[J], Journal of pharmacological sciences,2007, 104:82-89.
[127] Shin J S, Kim K S, Kim M B, et al. Synthesis and hypoglycemic effect of chrysin derivatives[J], Bioorganic & Medicinal Chemistry Letter, 1999, 9(6): 869-874.
[128] Suresh Babu K, Synthesis and biological evaluation of novel C (7) modified chrysin analogues as antibacterial agents[J], Bioorganic & Medicinal Chemistry Letters,2006,16: 221-224.
[129]于小凤,孙茂春,白雪洁等, NO供体黄酮类化合物的合成及生物活性研究.中国药物化学杂志[J], 2005,15(4):197-201.
[130] Gasco A M, Frutter R, Sorba G, et al. Phenylfuroxancarbaldehydes and related compounds[J], Liebigs Annalen der Chemie,1991,1111-1211.
[131] Sorba G, Medana C, Fruttero R, et al.Water soluble furoxan derivatives as NO prodrugs[J], J. Med. Chem, 1997,40: 463-469.
[132] Renodon-Comiere A,Dijols S,Perollier C,et a1.N-Aryl-N'-hydroxy guanidines, a new class of NO-donors after selective oxidation by nitric oxide synthases:structure-activity relationship[J].J Med Chem,2002,45(4):944-954.
[133]石卫兵,王未东,赖宜生,等.一氧化氮供体N-芳基-N′-羟基胍类化合物的合成[J].药学进展, 2005, 29 (11: 508-511.
[134] Aoki M, Preparation of carbonic acid esters of 2-hydroxyguanidines as intrmediates for dyes, photographic couplers, drugs, and pesticides[ P]. JP 2001316350A2, 2001.11.13
[135] Madar Z, Omunsky Z. Inhibition of intestinalα-glucosidase activity and postpradial hyperglycemia byα-glucosidase inhibitors in fa/fa rats[J]. Nutr. Res., 1991, 11, 1035-1046.
[136] DeBouno J F, Michaelis O E, et al.. The effects of the intestinal glucosidase inhibitor Bay M 1099(miglitol) on glycemic status of obese-diabetic rats[J]. Gen. Pharamic., 1993, 24: 509-515.。
[137] Saul R, Chambers J P, Molyneux R J, et al.. Castanospermine, a Tetrahydroxylated Alkaloid that Inhibits beta-Glucosidase and beta-Glucocerrebrosidase[J]. Archives of Biochemistry and Biophysics. 1983, 221(2): 593-597.
[138] Atsumi S, Kazuo Umezawa, et al.. Production, isolation and structure determination of a novelβ-Glucosidase and inhibitor,cyclophellitol[J]. The Journal of Antibiotics, 1990, 43(1): 49-53.
[139] Kurihara H, Masayoshi Sasaki, et al.. A New Screening Method for Glucosidase Inhibitors and its Application to Algal Extracts[J]. Fisheries Science, 1994, 60(6): 759-761.。Part A Anat Re., 2001,264(4):317-324
[140] Mosmann T. Rapid Colorimetric assay for cellular growth and survival; application to proliferation and cytotoxicity assays. J Immuno Medthods,1983,65(1-2):55-63Journal of Immunological Methods Volume 65, Issues 1-2, 16 December 1983, Pages 55-63
[141] Bootle-Wilbraham C A, Tazzyman S, Thompson W D, et a1.Fibrin fragment E stimulates the proliferation, migration and differentiation of human microvascular endothelial cells in vitro [J].Angiogenesis,2001,4(4):269-275
[142] Domenico Ribatti, Beatrice Nico, Angelo Vacca , et a1.Chorioallantoic membrane capillary bed: A useful target for studying angiogenesis and anti-angiogenesis in vivo [J].The Anatomical Record Part A Anat Re., 2001,264(4):317-324
[143] Thompson T W D, Reid A.Quantitative assays for the chick chorioallantoic membrane [J]. Adv Exp Med Biol, 2000,476:225-229.
[144] Liu J M, Lawrence F, Kovacevic M, Bignon J, Papadimitriou E, Lallemand J Y, Katsoris P, Potier P, Fromes Y, et al. The tetrapeptide AcSDKP, an inhibitor of primitive hematopoietic cell proliferation, induces angiogenesis in vitro and in vivo[J]. Blood , 2003, 101(8): 3014-3020.
[145] Yan X, Lin Y, Yang D, et al. A novel anti-CD146 monoclonal antibody, AA98, inhibits angiogenesis and tumor growth[J]. Blood, 2003, 102(1): 184-191.
[146] Vacca A, Ribatti D, Presta M, et al. Bone marrow neovascularization, plasma cell angiogenic potential, and matrix metalloproteinase-2 secretion parallel progression of human multiple myeloma[J]. Blood,1999, 93(9): 3064-3073.
[147] Strick D M,Waycaster R L,Montani J P,et a1.Morphometric measurements of chorioallantoic membrane vascularity:effects of hypoxia and hyperoxia[J].Am J Physiol,1991,260(4 Pt 2):1 385-1389.
[148] Santulli R J, Kinney W A, et al. Studies with an orally bioavailable alpha V integrin antagonist in animal models of ocular vasculopathy: retinal neovascularization in mice and retinal vascular permeability in diabetic rats[J]. J Pharmacol Exp Ther 2008 324(3): 894-901.
[149]] Colman R W, Jameson B A, Lin Y, et al. Domain 5 of high molecular weight kininogen (kininostatin) down-regulates endothelial cell proliferation and migration and inhibits angiogenesis[J]. Blood, 2000, 95(2): 543-550.
[150] Dusseau J W, Hutchins P M and Malbasa D S, et al. Stimulation of angiogenesis by adenosine on the chick chorioallantoic membrane[J].Circulation Research. 1986; 59: 163-170.
[151] Wu G Y, Brosnan J T , Macrophages can convert citrulline into arginine[J], Biochem J, 1992, 281(1): 45-48.
[152] Verdon C P, Burton B A, Prior R L, et a1. Sample pretreatment with nitrate reductase and glucose-6-phosphate dehydrogenase quantitatively reduces nitrate while avoiding interference by NADP+ when the Griess reaction is used to assay for nitrite[J], Anal Biochem,1995,1224:502-508.
[153] Archer S. Measurement of nitric oxide in biological models[J], The FASEB Journal, 1993, 7: 349-360.